PBAC's latest decision on Olmesartan medoxomil with amlodipine: Recommended with restriction (2010). Considered for Hypertension in patients who are not adequately controlled with either angiotensin II receptor antagonist or dihydropyridine calcium channel blocker monotherapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.
Therapy area
Cardiovascular
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
DBP reduction
Key trials
Trial 302, Trial 303, COACH trial
Comparator
olmesartan medoxomil and amlodipine given concomitantly
Economic model
Cost-minimisation
Budget impact
$-10000000
ICER note
Cost-minimisation analysis performed; no ICER calculated